Clinical Trial Update: Persistence of Antibodies and Kinetics of B Cell Response in Healthy Children After Vaccination With MCC Vaccine [Phase 4]

View source ↗

Summary

A Phase 4 study reports on durability of antibody responses and B cell kinetics in healthy children after MCC meningococcal vaccination.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections
• Meningococcal Meningitis

Drugs mentioned

• MCC Vaccine (Meningococcal C conjugate vaccine)

Snippet

Sponsor: Novartis Vaccines | Conditions: Prevention of Meningococcal Infection | Phase 4 | Status: COMPLETED